Prospective, clinical intervention study wasconducted from March 2021 to October 2021 on 90 patients, randomly divided into 3 groups: group I - sugammadex 1mg / kg, group II - sugammadex 0.5mg / kg, group III - neostigmine 40mcg / kg with atropine sulphate 15 mcg/kg.